These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 1527321)

  • 21. Risk assessment of Hymenoptera re-sting frequency: implications for decision-making in venom immunotherapy.
    von Moos S; Graf N; Johansen P; Müllner G; Kündig TM; Senti G
    Int Arch Allergy Immunol; 2013; 160(1):86-92. PubMed ID: 22948338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allergens of hymenopteran venoms.
    King TP; Valentine MD
    Clin Rev Allergy; 1987 May; 5(2):137-48. PubMed ID: 3581009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibodies to purified bee venom proteins and peptides. II. A detailed study of changes in IgE and IgG antibodies to individual bee venom antigens.
    Kemeny DM; MacKenzie-Mills M; Harries MG; Youlten LJ; Lessof MH
    J Allergy Clin Immunol; 1983 Oct; 72(4):376-85. PubMed ID: 6619452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hymenoptera venom allergy.
    Przybilla B; Ruëff F
    J Dtsch Dermatol Ges; 2010 Feb; 8(2):114-27; quiz 128-30. PubMed ID: 19751222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria for insect-venom hypersensitivity do not predict the occurrence and the severity of anaphylaxis.
    van der Linden PW; Hack CE; Struyvenberg A; van der Zwan JK
    J Allergy Clin Immunol; 1994 Aug; 94(2 Pt 1):151-9. PubMed ID: 8064067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clustered immunotherapy with Yellow Jacket venom. Evaluation of the influence of time interval on in vivo and in vitro parameters.
    Malling HJ; Djurup R; Søndergaard I; Weeke B
    Allergy; 1985 Jul; 40(5):373-83. PubMed ID: 4037258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Case report of venom immunotherapy for a patient with large local reactions.
    Hamilton RG; Golden DB; Kagey-Sobotka A; Lichtenstein LM
    Ann Allergy Asthma Immunol; 2001 Aug; 87(2):134-7. PubMed ID: 11527245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose dependence of Hymenoptera venom immunotherapy.
    Golden DB; Kagey-Sobotka A; Valentine MD; Lichtenstein LM
    J Allergy Clin Immunol; 1981 May; 67(5):370-4. PubMed ID: 7229226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discontinuation of yellow jacket venom immunotherapy: follow-up of 75 patients by means of deliberate sting challenge.
    van Halteren HK; van der Linden PW; Burgers JA; Bartelink AK
    J Allergy Clin Immunol; 1997 Dec; 100(6 Pt 1):767-70. PubMed ID: 9438484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Venom immunotherapy: tolerance to a 3-day protocol of rush-immunotherapy.
    Díez Gómez ML; Quirce Gancedo S; Juliá de Páramo B
    Allergol Immunopathol (Madr); 1995; 23(6):277-84. PubMed ID: 8579006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Intolerance of specific immunotherapy with Hymenoptera venom: jumping the hurdle with omalizumab].
    Wieczorek D; Kapp A; Wedi B
    Hautarzt; 2014 Sep; 65(9):791-5. PubMed ID: 25234627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rush hymenoptera venom immunotherapy is efficacious and safe.
    Pasaoglu G; Sin BA; Misirligil Z
    J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy with aluminum hydroxide adsorbed insect venom extracts (Alutard SQ): immunologic and clinical results of a prospective study over 3 years.
    Wyss M; Scheitlin T; Stadler BM; Wüthrich B
    Allergy; 1993 Feb; 48(2):81-6. PubMed ID: 8457037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rush Hymenoptera venom immunotherapy: successful treatment in a patient with systemic mast cell disease.
    Engler RJ; Davis WS
    J Allergy Clin Immunol; 1994 Sep; 94(3 Pt 1):556-9. PubMed ID: 8083461
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of the allergenicity and antigenicity of Polistes venom and other vespid venoms.
    Reisman RE; Wypych JI; Mueller UR; Grant JA
    J Allergy Clin Immunol; 1982 Oct; 70(4):281-7. PubMed ID: 6811646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Basophil degranulation test (BDT) as a parameter of hyposensitization with Hymenoptera venoms].
    Dietschi R; Wüthrich B; Marti-Wyss S; Cuhat J
    Schweiz Med Wochenschr; 1987 Oct; 117(44):1728-35. PubMed ID: 3685930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in IgG and IgE antibody levels to bee venom during immunotherapy.
    Ferrante A; Mocatta F; Goh DH
    Int Arch Allergy Appl Immunol; 1986; 81(3):284-7. PubMed ID: 3770979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols.
    Birnbaum J; Charpin D; Vervloet D
    Clin Exp Allergy; 1993 Mar; 23(3):226-30. PubMed ID: 8472191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A controlled trial of immunotherapy in insect hypersensitivity.
    Hunt KJ; Valentine MD; Sobotka AK; Benton AW; Amodio FJ; Lichtenstein LM
    N Engl J Med; 1978 Jul; 299(4):157-61. PubMed ID: 78446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allergy to venom from bee or wasp: the relation between clinical and immunological reactions to insect stings.
    Heinig JH; Engel T; Weeke ER
    Clin Allergy; 1988 Jan; 18(1):71-8. PubMed ID: 3349594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.